Doing Well by Doing Good

At Regeneron, we believe in "doing well by doing good." We not only work to invent new and needed medicines; we also are focused on improving our world and operating with the highest standards of integrity. We are proud not only of what we do, but how we do it.

Science, Technology, Engineering and Math (STEM) education is at the heart of our corporate citizenship efforts, representing more than 90 percent of our citizenship investments. We are deeply committed to supporting the development of highly engaged, well-trained, and innovative young thinkers.

We focus on programs that support, challenge and reward the best and brightest minds in science research, increase the effectiveness of teachers in STEM and bridge STEM skills gaps and career awareness among students historically underrepresented in the sciences.

A long-standing commitment to science education

  • - Science Research Mentorship Program
  • - Westchester Science & Engineering Fair
  • - College Internship Program
  • - Postdoctoral Fellowship
  • - Regeneron Prize for Creative Innovation
  • - Society for Science & the Public Science News in High Schools
  • - STEM Teaching Fellowship
  • - BioBus
  • - Sci2Med Academy

Explore our STEM programs


Regeneron is a leading science and technology company delivering life-transforming medicines for serious diseases. Founded by physician-scientists nearly 30 years ago, our science-focused approach has resulted in four FDA-approved medicines, and numerous product candidates to treat cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.

The discovery and development of our medicines was enabled by our groundbreaking VelociSuite® genetic and antibody technology platforms. We are also home to the Regeneron Genetics Center – one of the world’s largest, integrated programs of its kind.

We harness the power of science to transform lives.


  • 28
    of scientific
  • 4,500+
    employees worldwide
  • 630
    employees with
    an MD, PhD, or
    PharmD degree
  • 4TH
    Most Innovative
    Company, according
    to Forbes
  • 5 YRS
    Ranked #1 or #2 employer in the global
    biopharmaceutical industry in Science
    Top Employers Survey 5 years in a row
  • 4
  • 2,118
    volunteer hours at 66
    organizations through
    Regeneron in the
  • 100%
    of drug candidates
    invented and
    developed in-house
  • 100,000
    consented individuals
    sequenced by the
    Regeneron Genetics Center
  • 68
    in 2015
  • 12
    antibodies in clinical
    trials across multiple
    therapeutic areas
  • Fortune: Best Companies to Work For, 2016
    Barron's: World's Best CEOs, 2016
    Crain's New York Business: Fast 50, 2015
    Science: Top Employer, 2015
  • Forbes: World's Most Innovative Companies, 2015
    Shingo Prize: Operational Excellence, 2013
    Scrip Award: Clinical Advance of the Year, 2013
    Scrip Award: Management Team of the Year, 2013


Regeneron is led by two physician-scientists, who, remarkably, are both alumni of the STS competition.

Leonard S. Schleifer, MD, PhD, Founder, President, CEO and 1970 STS semifinalist, founded the company in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College.

He quickly approached George Yancopoulos, MD, PhD, a 28-year-old Professor of Biology at Columbia University, to join him in the new endeavor. The son of Greek immigrants, George had been driven to succeed in science his whole life and was also a top STS winner in 1976 while attending the Bronx High School of Science. Like Len, he grew up in Queens, New York, but the two had never met. In 1989, George joined the company as Founding Scientist and President of Regeneron Laboratories. He later became a member of the National Academy of Sciences, which is virtually unheard of for an industry scientist, and was the 11th most highly cited scientist in the world in the 1990s.

Leveraging a lifelong passion for science and an entrepreneurial spirit, Len and George were able to secure $1 million in venture funding from Merrill Lynch. Recognizing the critical value of scientific mentorship and expertise, they began recruiting top scientists to serve as company advisors, including multiple Nobel Prize winners to join the Board of Directors.

In 1995, Len and George approached one such scientific luminary, Roy Vagelos, MD, who was retiring as Merck CEO and Chairman, to join Regeneron as Chairman of the Board. One of the most respected leaders in science and business, Roy had built Merck into a scientific and drug development powerhouse, and just as importantly, set a new standard in corporate citizenship. During Roy's tenure, Merck was named the most trusted company in America.

The company benefits from one of the longest-standing and distinguished Board of Directors, including two Nobel Laureates and six members of the National Academy of Sciences. Demonstrating the company's commitment to scientific excellence, Regeneron was one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice that has since become industry standard.

Learn more about Len
Learn more about George



  • 1988
  • 1989
  • 1990
  • 2003
  • 2006
  • 2007
  • 2008
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 1988

    Regeneron is founded by Leonard S. Schleifer, MD, PhD,
    young neurologist and assistant professor at Cornell University Medical College

  • 1989

    George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, joins Regeneron as Founding Scientist, and becomes the 11th most highly cited scientist in the world during the 1990s

  • 1990

    Science publishes first Regeneron paper, which becomes the most highly cited neurobiology paper of the year; company announces collaboration to develop neurotrophic factors

  • 2003

    First paper on VelociGene® is published, introducing the world to proprietary Veloci technologies;
    Regeneron becomes one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

  • 2006

    Sarilumab, our first fully human antibody, enters clinical development;
    Collaboration with Bayer HealthCare focuses on developing EYLEA® (aflibercept) Injection outside the U.S.

  • 2007

    Regeneron begins a collaboration with Sanofi focused on developing fully human antibodies
    using our VelocImmune® technology platform

  • 2008

    FDA approves ARCALYST® (rilonacept) Injection

  • 2010

    Regeneron begins sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in under-served school districts

  • 2011

    Our President and CEO, Leonard S. Schleifer, is named Ernst & Young Entrepreneur Of The Year® 2011 New York Award Winner; FDA approves EYLEA® (aflibercept) Injection for a blindness-causing disease

  • 2012

    Science Top Employer survey names Regeneron #1 employer in the global biopharmaceutical industry;
    Scrip Intelligence names us Biotech Company of the Year

  • 2013

    Regeneron launches and announces the first recipients of our annual "Regeneron Prize for Creative Innovation"; European business office opens in Dublin, Ireland; Scrip Intelligence names CEO and CSO "Management Team of the Year"

  • 2014

    Regeneron launches the Regeneron Genetics Center, a new human genetics initiative; Launches STEM Teaching Fellowship, a joint effort with the STEM Leadership Center to develop a highly trained science teacher community; Launches Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields; FDA grants investigational antibody dupilumab a Breakthrough Therapy designation; Regeneron begins planning first ex-U.S. IOPS site in Limerick, Ireland

  • 2015

    Top Employers Survey ranks us #1 or #2 employer in the global biopharmaceutical industry 5 years in a row; FDA approves PRALUENT® (alirocumab) Injection, our fourth FDA-approved medicine and first fully human monoclonal antibody; Regeneron enters into an agreement with the U.S. government for the development of a new antibody treatment for the Ebola virus; Regeneron launches a major new immuno-oncology collaboration with Sanofi

  • 2016

    FDA accepts our Biologics License Application for the review and potential approval of sarilumab


    We are proud to have several STS alumni among our employee base, including Leonard S. Schleifer, MD, PhD, our Founder, President and Chief Executive Officer, and George Yancopoulos, MD, PhD, our Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer.

As our company grows,
so does our commitment
to future scientists.

We are honored to announce our support of the next
generation of groundbreaking minds.

Learn more